Sp499
HOW HAS FDA APPROVAL CHANGED THE LANDSCAPE OF MICROBIOME THERAPEUTICS
Date
May 19, 2024
Tracks
Related Products
ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY
Background: We compared real-world outcomes of upadacitinib (upa) vs tofacitinib (tofa) for ulcerative colitis (UC) through 52 weeks…
AGA How Do We End the Arms Race Between Commensals and Opportunistic Pathogens in the Gut?
The gastrointestinal tract is a diverse and complex ecosystem shaped by continual interactions between host cells, nutrients, and the gut microbiota. Under homeostatic conditions, the human gut microbiota limits the growth of pathogenic bacteria and restricts the influence of resident pathobionts…
USE OF TRAMADOL VERSUS TRADITIONAL OPIOIDS AND ADVERSE OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A DANISH NATIONWIDE COHORT STUDY
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…